{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:58:31Z","timestamp":1792785511572,"version":"4.5.0"},"reference-count":141,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"No funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.1080\/17512433.2024.2317954","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T05:56:41Z","timestamp":1707544601000},"page":"537-547","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics"],"prefix":"10.1080","volume":"17","author":[{"given":"Nicole F.","family":"Maranchick","sequence":"first","affiliation":[{"name":"University of Florida","place":["Gainesville, USA"]},{"name":"University of Florida","place":["Gainesville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[{"name":"University of Florida","place":["Gainesville, USA"]},{"name":"University of Florida","place":["Gainesville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"University of Florida","place":["Gainesville, USA"]},{"name":"University of Florida","place":["Gainesville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"e_1_3_4_4_1","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","year":"2021","unstructured":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2017.128"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/518657"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.04.009"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001313"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905848"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25772"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2020.05.004"},{"issue":"6","key":"e_1_3_4_12_1","first-page":"696","article-title":"Factors associated with tuberculosis treatment success among tuberculosis and human immunodeficiency virus co-infected patients in Kelantan","volume":"77","author":"Romaino SMN","year":"2022","unstructured":"Romaino SMN, Naing NN, Mat Zuki MJ. Factors associated with tuberculosis treatment success among tuberculosis and human immunodeficiency virus co-infected patients in Kelantan. Med J Malaysia. 2022;77(6):696\u2013703.","journal-title":"Med J Malaysia"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507198"},{"key":"e_1_3_4_15_1","unstructured":"CDC. Managing drug interactions in the Treatment of HIV-Related tuberculosis [online]. 2013. Available from: http:\/\/www.cdc.gov\/tb\/TB_HIV_Drugs\/default.htm"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013911"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013607"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2979"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir230"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1694901"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17141-9"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90693-9"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1981.123.4.367"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003259220"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6663"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.144.8.1667"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016196"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.04.009"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318276cda9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz256"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac585"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00081-4"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002126"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01468-08"},{"key":"e_1_3_4_36_1","volume-title":"Isentress (raltegravir) [prescribing information]","year":"2023","unstructured":"Isentress (raltegravir) [prescribing information]. Whitehouse Station NJ: Merck & Co., Inc; 2023 Jun."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70711-X"},{"key":"e_1_3_4_38_1","volume-title":"(Bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]","author":"Biktarvy","year":"2018","unstructured":"Biktarvy. (Bictegravir, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City CA: Gilead Sciences, Inc.; 2018 Feb."},{"key":"e_1_3_4_39_1","volume-title":"Presented at: Conference on Retroviruses and Opportunistic Infections","author":"Custodio J","year":"2018","unstructured":"Custodio J, West SK, Collins S, et al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. Presented at: Conference on Retroviruses and Opportunistic Infections; 2018. Boston, MA. Available from: https:\/\/www.croiconference.org\/sessions\/pharmacokinetics-bictegravir-administered-twice-daily-combination-rifampin"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00487-17"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac901"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy726"},{"key":"e_1_3_4_43_1","volume-title":"Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]","year":"2015","unstructured":"Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City CA: Gilead Sciences Inc; 2015 Jul."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz068"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2023.10.011"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00987.x"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.7.1426"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.1.2101133"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318189a7df"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282faa71e"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1553-1560.2004"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01598-10"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab097"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz522"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv439"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19586"},{"key":"e_1_3_4_57_1","volume-title":"Reyataz (atazanavir) [prescribing information]","year":"2020","unstructured":"Reyataz (atazanavir) [prescribing information]. Princeton NJ: Bristol-Myers Squibb Company; 2020 Sep."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad700"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/09564624221134137"},{"key":"e_1_3_4_60_1","volume-title":"Efavirenz (Sustiva\u00ae) prescribing information","year":"2002","unstructured":"Efavirenz (Sustiva\u00ae) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company; 2002."},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241090-00004"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit246"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy491"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku348"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir447"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.5.530"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.06.016"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq411"},{"key":"e_1_3_4_69_1","volume-title":"Edurant\u00ae (rilpivirine) [prescribing information]","author":"US Food and Drug Administration","year":"2011","unstructured":"US Food and Drug Administration. Edurant\u00ae (rilpivirine) [prescribing information]. Raritan NJ: Tibotec Pharmaceuticals Inc. 2011."},{"key":"e_1_3_4_70_1","volume-title":"Edurant (rilpivirine) [prescribing information]","year":"2021","unstructured":"Edurant (rilpivirine) [prescribing information]. Titusville NJ: Janssen Products LP; 2021."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.2165\/11534740-000000000-00000"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0513-4"},{"key":"e_1_3_4_73_1","volume-title":"Pifeltro (doravirine) [prescribing information]","year":"2018","unstructured":"Pifeltro (doravirine) [prescribing information]. Whitehouse Station NJ: Merck & Co Inc; 2018 Aug."},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03134.x"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_1.S15"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-2797(97)00071-9"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0068"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25333"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15604"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582221111077"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3306"},{"key":"e_1_3_4_82_1","volume-title":"Vocabria (cabotegravir) tablets [prescribing information]","year":"2021","unstructured":"Vocabria (cabotegravir) tablets [prescribing information]. Research Triangle Park NC: ViiV Healthcare; 2021 Dec."},{"key":"e_1_3_4_83_1","volume-title":"Apretude (cabotegravir) extended-release injectable suspension [prescribing information]","year":"2021","unstructured":"Apretude (cabotegravir) extended-release injectable suspension [prescribing information]. Research Triangle Park NC: ViiV Healthcare; 2021 Dec."},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010375959"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.09.1423"},{"key":"e_1_3_4_86_1","volume-title":"Mycobutin (rifabutin) [prescribing information]","year":"2007","unstructured":"Mycobutin (rifabutin) [prescribing information]. (NY) NY: Pfizer Inc; 2007."},{"key":"e_1_3_4_87_1","volume-title":"Kaletra (lopinavir\/ritonavir) [prescribing information]","unstructured":"Kaletra (lopinavir\/ritonavir) [prescribing information]. North Chicago IL: AbbVie Inc."},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-15-61"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv470"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1086\/429321"},{"key":"e_1_3_4_91_1","volume-title":"Program And Abstracts Of The Infectious Diseases Society (Denver)","author":"Benedek IH","unstructured":"Benedek IH, Fiske WD, White SJ, et al. Pharmacokinetic interaction between multiple doses of efavirenz (EFV) and rifabutin in healthy volunteers [abstract 461]. Program And Abstracts Of The Infectious Diseases Society (Denver). 1998."},{"key":"e_1_3_4_92_1","volume-title":"Atripla (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]","year":"2019","unstructured":"Atripla (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City CA: Gilead Sciences Inc; 2019."},{"key":"e_1_3_4_93_1","volume-title":"Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) [prescribing information]","year":"2019","unstructured":"Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) [prescribing information]. Morgantown WV: Mylan Specialty LP; 2019."},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1086\/496980"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090516"},{"key":"e_1_3_4_96_1","article-title":"Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifabutin (RFB)","author":"Maldonado S","unstructured":"Maldonado S, Lamson M, Gigliotti M, et al. Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifabutin (RFB). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (CA). 1999 Sep.","journal-title":"39th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"e_1_3_4_97_1","volume-title":"Viramune (nevirapine) [prescribing information]","year":"2018","unstructured":"Viramune (nevirapine) [prescribing information]. Ridgefield CT: Boehringer Ingelheim Pharmaceuticals Inc; 2018."},{"key":"e_1_3_4_98_1","volume-title":"Cabenuva (cabotegravir) extended-release injectable solution [product monograph]","year":"2021","unstructured":"Cabenuva (cabotegravir) extended-release injectable solution [product monograph]. Research Triangle Park NC: ViiV Healthcare; 2021."},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1103"},{"key":"e_1_3_4_100_1","volume-title":"Intelence (etravirine) [prescribing information]","year":"2018","unstructured":"Intelence (etravirine) [prescribing information]. Titusville NJ: Janssen Therapeutics; 2018 Nov."},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0144-3"},{"issue":"4","key":"e_1_3_4_105_1","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan JE","year":"2009","unstructured":"Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR\u20134):1\u2013207. quiz CE1-4","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30032-1"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt483"},{"key":"e_1_3_4_108_1","volume-title":"Presented at: Conference on Retroviruses and Opportunistic Infections","author":"Farenc C","year":"2014","unstructured":"Farenc C, Doroumian S, Cantalloube C, et al. Rifapentine once-weekly dosing effect on efavirenz emtricitabine and tenofovir PKs. Presented at: Conference on Retroviruses and Opportunistic Infections; 2014. Boston, MA. Available at: http:\/\/www.croiconference.org\/sessions\/rifapentine-once-weekly-dosing-effect-efavirenz-emtricitabine-and-tenofovir-pks. Presented at"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02385-21"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25844"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017863"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku171"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12722"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30770-2"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182410503"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00191-13"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv447"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab335"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx004"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1086\/518655"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13018"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-81"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0170-1"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0029-2016"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0716-8"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.180"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.22.0448"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1610.100374"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2011.12.001"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0222-8"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2017.37.2.97"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00185-07"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-09"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1063453"},{"issue":"12","key":"e_1_3_4_137_1","first-page":"e01092","article-title":"Population pharmacokinetic Model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients","volume":"62","author":"van den Elsen SHJ","year":"2018","unstructured":"van den Elsen SHJ, Sturkenboom MGG, van\u2019t Boveneind-Vrubleuskaya N, et al. Population pharmacokinetic Model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients. Antimicrob Agents Chemother. 2018;62(12):e01092\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00176610"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis270"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2010.0370"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3966-3969.2005"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100793"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28083342"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2024.2317954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:56:34Z","timestamp":1756720594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2024.2317954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":141,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["10.1080\/17512433.2024.2317954"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2024.2317954","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}